Lung cancer
Conditions
Interventions
Induction therapy with afatinib combined with pemetrexed/platinum-based chemotherapy group:Nil
Induction therapy with gefitinib combined with pemetrexed/platinum-based chemotherapy group:Nil
Sponsors
Shandong Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Non-squamous NSCLC patients confirmed by imaging and histopathology as III B to IV stage; 2.Positive EGFR gene mutation (including 19DEL, 21L858R, G719A, G719C, G719S, L861Q, V689M, N700D, E709K/Q, S720P, L858R, N826S, A839T, K846R, G863D, G719X, S768I complex mutation, G719X complex mutation, etc.); 3.Has not received any previous systemic anti-tumor therapy; 4.No brain metastases, or asymptomatic brain metastases, or symptomatic brain metastases are treated and stable.
Exclusion criteria
Exclusion criteria: 1.Patients with wild type EGFR gene; 2.Do not receive chemotherapy or are estimated to be intolerable to chemotherapy; 3.Previous chemotherapy or EGFR-TKIs treatment; 4.Patients received adjuvant or neoadjuvant therapy and the time from the last treatment to recurrence was less than 6 months; 5.The Investigator considers the patient unsuitable for participation in any other condition of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival;safety and tolerability characteristics; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;objective remission rate;disease control rate; | — |
Countries
China
Contacts
Public ContactWang Zhehai
Shandong Cancer Hospital
Outcome results
None listed